PSAD联合PI-RADS 2.1评分预测前列腺癌能力研究

中老年男性泌尿系统常见的恶性肿瘤之一是前列腺癌；前列腺特异性抗原及其衍生指标与前列腺磁共振检查前列腺影像报告和数据系统2.1版本（prostate imaging reporting and data system 2.1，PI-RADS 2.1）评分是临床选择治疗方案、评价疗效和随诊复查的主要检查方法。由于这2种检查方法诊断效能有差异，研究主要集中在前列腺特异性抗原衍生指标联合PI-RADS 2.1评分在预测临床有意义前列腺癌诊断价值这方面。多数文献提出前列腺特异性抗原衍生指标中前列腺特异性抗原密度（prostate specific antigen density，PSAD）诊断价值最高，因此笔者主要综述PSAD联合PI-RADS 2.1评分在预测临床有意义前列腺癌的诊断价值，并做出展望。

Study on the ability of PSAD combined with PI-RADS 2.1 score in predicting prostate cancer

Prostate cancer is one of the common malignant tumors of urinary system in middle-aged and elderly men. Prostate specific antigen and its derived indexes and prostate magnetic resonance examination prostate imaging reporting and data system 2.1 (PI-RADS 2.1) score are the main examination methods for clinical treatment scheme selection, curative effect evaluation, and follow-up review. Due to the difference in the diagnostic efficacy between the two methods, the researches mainly focus on the diagnostic value of prostate specific antigen-derived indexes combined with PI-RADS 2.1 score in predicting clinically significant prostate cancer. Most literatures have suggested that prostate specific antigen density (PSAD) has the highest diagnostic value among prostate specific antigen-derived indexes. Therefore, the authors mainly summarize the diagnostic value of PSAD combined with PI-RADS 2.1 score in predicting clinically significant prostate cancer, and make a prospect.